STEWARTVILLE, Minn., July 31 /PRNewswire-FirstCall/ -- Rochester
Medical Corporation (NASDAQ:ROCM) today announced operating results
for its third quarter ending June 30, 2007. The Company reported
record sales of $8,367,000 for the current quarter compared to
$5,358,000 for the third quarter of last year. It also reported net
income of $807,000 or $.06 per diluted share compared to a net
income of $985,000 or $.08 per diluted share for the third quarter
of last year. Net income excluding stock option expense, expense
for amortization of intangibles, and also excluding income tax
benefits from the realization of deferred assets; or "Non-GAAP Net
Income" for the current quarter is $1,315,000 or $.10 per diluted
share, compared to Non-GAAP Net Income of $305,000 or $.03 per
diluted share for the third quarter of last year. To aid in
analysis of the quarterly results, the Company also notes the
following: -- The results for the current quarter include an
expense of approximately $170,000 relating to enhancing IT systems
and implementing procedures needed to become compliant with Section
404 of Sarbanes-Oxley, which the Company is required to complete by
the end of this fiscal year. -- The results for the current quarter
reflect a planned increased investment in marketing and sales. The
Company expects this investment will lead to increased sales and
earnings in the future. The 56% increase in sales revenue for the
current quarter compared to last year's third quarter resulted from
increased sales of Rochester Medical branded products and from
increased Private Label sales. International sales resulting from
the acquired U.K. business generated a significant portion of the
increase. The increase in the Non-GAAP net income for the current
quarter is due to increased contribution from increased sales. "The
Company's performance is solid," said CEO Anthony J. Conway. "We
see increasing interest in our product lines and increasing
recognition of the Rochester Medical brand in the marketplace. We
expect continued success going forward." The Company will hold a
quarterly conference call this afternoon to discuss its earnings
report. The call will begin at 4:00 p.m. central time (5:00 p.m.
eastern time). This call is being webcast by Thomson Financial and
can be accessed at Rochester Medical's website at
http://www.rocm.com/. To listen live to the conference call via
telephone, call: Domestic: 1-800-831-6272, password 10254659
International: 1-617-213-8859, password 10254659 Replay will be
available for seven days at: http://www.rocm.com/ or via telephone:
Domestic Replay: 1-888-286-8010 password 88787377 International
Replay 1-617-801-6888, password 8778377 The webcast is also being
distributed through the Thomson StreetEvents Network to both
institutional and individual investors. Individual investors can
listen to the call at http://www.fulldisclosure.com/, Thomson
Financial individual investor portal, powered by StreetEvents.
Institutional investors can access the call via Thomson's
password-protected event management site, StreetEvents
(http://www.streetevents.com/). Rochester Medical has provided
Non-GAAP Net Income in addition to earnings calculated in
accordance with generally accepted accounting principles (GAAP)
because management believes Non-GAAP Net income provides a more
consistent basis for between quarter comparisons that are not
influenced by certain charges and non-cash expenses and are
therefore helpful in understanding Rochester Medical's underlying
operating results. Non-GAAP Net Income is not a measure of
financial performance under GAAP, and should not be considered an
alternative to net income or any other measure of performance or
liquidity under GAAP. Non-GAAP Net Income is not comparable to
information provided by other companies. Non-GAAP Net Income has
limitations as an analytical tool and should not be considered in
isolation or as a substitution for analysis of our results as
reported under GAAP. Reconciliations of Net Income and Non-GAAP Net
Income are presented at the end of this press release. This press
release contains forward-looking statements that involve risks and
uncertainties, including the uncertainty of estimated revenues and
profits, as well as the uncertainty of market acceptance of new
product introductions, the uncertainty of gaining new strategic
relationships or locating and capitalizing on strategic
opportunities, the uncertainty of timing of private label sales
revenues (particularly international customers), FDA and other
regulatory review and response times, and other risk factors listed
from time to time in the Company's SEC reports and filings,
including, without limitation, the section entitled "Risk Factors"
in the Company's Annual Report on Form 10-K for the year ended
September 30, 2006. Rochester Medical Corporation develops,
manufactures, and markets disposable medical catheters and devices
for urological and continence care applications. The Company
markets under its own Rochester Medical(R) brand and under existing
private label arrangements. For further information, please contact
Anthony J. Conway, President and Chief Executive Officer of
Rochester Medical Corporation at (507) 533-9600. More information
about Rochester Medical is available on its website at
http://www.rocm.com/. ROCHESTER MEDICAL CORPORATION Reconciliation
of Reported GAAP Net Income to Non-GAAP Net Income For the three
and nine months ended June 30, 2007 Three months ended Nine months
ended June 30, June 30, 2007 2006 2007 2006 GAAP Net Income as
Reported $807,000 $985,000 $33,317,000 $1,053,000 Diluted EPS as
Reported $0.06 $0.08 $2.69 $0.09 Adjustments for non- recurring
unusual items: Settlement income after taxes (1) - - (31,305,000) -
Deferred revenue (2) - (39,000) (564,000) (118,000) Deferred tax
benefit (3) - (759,000) - (759,000) Subtotal - (798,000)
(31,869,000) (877,000) Adjustments for recurring non-cash expenses:
Intangible Amortization (4) 163,000 30,000 490,000 30,000 FAS 123R
Compensation Expense (5) 345,000 88,000 1,806,000 504,000 Subtotal
508,000 118,000 2,296,000 534,000 Non-GAAP Net Income $1,315,000
$305,000 $3,744,000 $710,000 Non-GAAP Diluted EPS $0.10 $0.03 $0.30
$0.06 Weighted Average Shares - Diluted 12,565,278 11,837,710
12,400,531 11,652,584 (1) Settlement income received November 20,
2006 from Premier, Inc of $5,155,000 and December 14, 2006 from CR
Bard, Inc. of $33,450,000 after taxes. This adjustment reduces net
income for amounts received net of taxes paid in connection with
one-time settlement of certain litigation. These amounts were
recorded in Other Income in the Statement of Operations for the
nine months ended June 30, 2007. (2) Deferred revenue from a
$1,000,000 fee paid by Coloplast A/S in June 2002 for marketing
rights to our antibacterial Release NF foley catheter. These rights
have been cancelled by mutual agreement, thus accelerating the
recognition of the remaining amount as all conditions for revenue
recognition have now been met. Also includes a $250,000 fee paid by
Hollister for marketing rights to our hydrophilic intermittent
catheter in September 2003. This adjustment reduces net income
related to the realization of certain one-time revenue from
marketing rights. The amounts were recorded in net sales in the
Statement of Operations for the nine months ended June 30, 2007.
(3) Increase in the deferred tax asset which resulted in a tax
benefit and an increase in earnings. This adjustment reduces net
income for certain one-time tax benefits recorded in the three and
nine months ended June 30, 2006. (4) Amortization of the
intangibles acquired in June 2006 asset acquisition from Coloplast
AS and Mentor Corporation. Management believes these assets are
appreciating. This adjustment adds back amortization expense for
the three and nine months ended June 30, 2007 related to certain
intangibles. (5) Compensation expense mandated by SFAS 123R. This
adjustment adds back the compensation expense recorded when stock
options are granted to employees and directors for the three and
nine months ended June 30, 2007. Condensed Balance Sheets
(unaudited) June 30, September 30, 2007 2006 Assets Current Assets
Cash and equivalents $7,671,267 $2,906,698 Marketable securities
30,311,938 - Accounts receivable 5,665,945 4,494,094 Inventories
7,046,042 4,642,578 Prepaid expenses and other assets 494,417
410,267 Deferred income tax asset 900,000 53,000 Total current
assets 52,089,609 12,506,637 Property and equipment 9,410,980
8,239,246 Deferred income tax asset 415,000 1,178,000 Patents, net
264,246 271,171 Intangible assets, net 7,780,012 8,270,157 Goodwill
5,430,176 5,487,141 Total Assets $75,390,023 $35,952,352
Liabilities and Stockholders' Equity Current liabilities: Accounts
payable $1,485,824 $1,278,441 Accrued expenses 1,038,094 1,621,376
Short term debt 1,731,825 1,681,361 Current maturities of capital
leases - 42,084 Income taxes payable 1,641,372 105,559 Deferred
revenue - 114,287 Total current liabilities 5,897,115 4,843,108
Long-term liabilities Long term debt 6,024,445 7,540,737 Capital
leases, less current portion - 21,946 Deferred revenue - 449,999
Total long term liabilities 6,024,445 8,012,682 Stockholders'
equity 63,468,463 23,096,562 Total Liabilities and Stockholders'
Equity $75,390,023 $35,952,352 Summary Statements Of Operations
Three months ended Nine months ended June 30, June 30, 2007 2006
2007 2006 Sales $8,367,140 $5,358,076 $24,225,709 $14,839,355 Cost
of sales 3,918,614 3,361,907 11,574,203 9,682,200 Gross profit
4,448,526 1,996,169 12,651,506 5,157,155 Gross profit % 53% 37% 52%
35% Costs and expense: Marketing and selling 1,809,928 786,583
4,564,275 1,961,950 Research and development 267,235 209,060
710,500 569,657 General and administrative 1,443,932 788,584
5,202,631 2,355,384 Total operating expenses 3,521,095 1,784,227
10,477,406 4,886,991 Income from operations 927,431 211,942
2,174,100 270,164 Other income (expense) (Loss) on sale of
investments - - - (103,532) Interest income 393,594 70,933 907,947
188,379 Interest expense (89,626) (56,377) (402,448) (61,451) Other
income - - 38,605,000 - Net income before income taxes $1,231,399
$226,498 $41,284,599 $293,560 Income tax expense (benefit) 424,836
(758,991) 7,967,902 (758,991) Net income 806,563 985,489 33,316,697
1,052,551 Earnings per common share - Basic $0.07 $0.09 $2.93 $0.10
Earnings per common share - Diluted $0.06 $0.08 $2.69 $0.09
Weighted Average Shares: 11,649,268 11,072,988 11,371,894
11,064,224 Basic Weighted Average Shares: Diluted 12,565,278
11,837,710 12,400,531 11,652,584 DATASOURCE: Rochester Medical
Corporation CONTACT: Anthony J. Conway, President and Chief
Executive Officer of Rochester Medical Corporation, +1-507-533-9600
Web site: http://www.rocm.com/
Copyright
Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From May 2024 to Jun 2024
Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From Jun 2023 to Jun 2024